Agios Pharmaceuticals Announces Initiation Of Four Expansion Cohorts In Phase 1 Study Of AG-221

Agios Pharmaceuticals, Inc.

, a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced the initiation of four expansion cohorts in its ongoing Phase 1 study of AG-221, a first-in-class, selective, potent IDH2 mutant inhibitor. The Phase 1 expansion cohorts will assess the safety and tolerability of AG-221 at 100 mg once daily in approximately 100 patients with IDH2-mutant hematologic malignancies, including acute myelogenous leukemia (AML). Members of Agios' management team will provide an overview of this trial expansion at its Research and Development (R&D) Day meeting today. "AG-221 is the first targeted investigational medicine to show clinical activity in patients with an IDH2 mutation, validating IDH2 as an important target for patients with AML and potentially other cancers," said David Schenkein, M.D., chief executive officer at Agios. "Having selected the dose of AG-221 based on our ongoing Phase 1 study, we are now advancing to the next stage of development." "At our R&D Day today, we will delve deeply into the science of Agios. We will also highlight the disease areas in which we believe our precision medicine approach has the potential to establish new treatment paradigms and deliver important medicines to patients. We are encouraged by the progress of all three of our investigational medicines and look forward to presenting data from our Phase 1 study of AG-120 at EORTC-NCI-AACR in November, as well as data from AG-221 and AG-348 studies at the 2014 American Society of Hematology Annual Meeting in December," Dr. Schenkein continued. Webcast A live webcast of the company's R&D Day will begin today at 9:00 a.m. EDT and can be accessed under "Events & Presentations" in the Investors and Media section of the company's website at agios.com. A replay of the webcast will be archived on the Agios website for 30 days following the presentation.